【摘要】 目的研究在无症状的肺癌高危人群中低剂量CT(LDCT)联合血清P16基因甲基化检测对肺癌早期诊断的可行性。方法405例受试者随机分入LDCT+P16甲基化检测组(221例)和前后位胸片(CXR)组(184例)。入选标准为男性,55~75岁,吸烟指数≥200年支。结果LDCT+P16甲基化组97.7%(216例)和CXR组93.5%(173例)的受试者完成检测。LDCT+P16甲基化组与CXR组分别有22例(10.2%)和13例(7.5%)可疑肺癌,3例及1例确诊肺癌。结论LDCT联合P16基因甲基化检测比CXR检查发现更多的肺癌。更多还原

【Abstract】 Objective To determine the feasibility of conducting low-dose computed tomography (LDCT) and serum P16 gene methylation measurement for early diagnosis of lung cancers in symptomatic individuals at high risk of lung cancer. Methods 405 patients were randomly divided into two groups:LDCT+ P16 gene methylation measurement group(221 cases)and posterio-anterior view chest X-ray (CXR) examination group(184 cases).Inclusion criteria was defined as male measurement,aged from 55 to 75, smoking over 200 cigarettes per year. Results The experiment was completed in 97.7%(216 patients)of the LDCT+P16 group, and in 93.5%(173 patients) of the CXR group. 22 patients(10.2%)in the LDCT+P16 group and 13 patients(7.5%)in the CXR group were suspicious for lung cancer. A total of 3 cases of lung cancer in the LDCT +P16 group and 1 case in the CXR group were diagnosed. Conclusions More lung cancer cases can be detected through LDCT plus P16 gene methylation measurement than CXR.更多还原